Korea South
Bertis Inc is a proteomics-based molecular diagnostics company with a primary focus on discovering cancer-related biomarkers. The company's proteomics technology offers diagnostic services for early detection of cancer and various diseases, utilizing advanced techniques to analyze hundreds of proteins accurately and meticulously. Founded in 2014, Bertis Inc has emerged as a prominent player in the biotechnology and healthcare industries, with its headquarters based in South Korea.
About a decade ago, in a time when proteomics did not garner significant attention in Korea, Bertis Inc took the initiative to pursue scientific research in this field, recognizing its global potential. Leveraging a unique technology based on 25 million protein big data and A. I., the company has made considerable advancements and aims to expand its operations beyond Korea to become a global leader in proteomics. Bertis Inc actively engages with experts from diverse fields, collaborating with physicians, chemists, biologists, and engineers to drive innovation.
The latest investment of KRW15.00B in a venture round was secured on 03 June 2021, with participation from SK Planet and SK Telecom as key investors. With its progressive approach and groundbreaking technology, Bertis Inc is poised for significant growth and impact in the field of molecular diagnostics and cancer research.
